EP0941120A4 - Branched peptide linkers - Google Patents

Branched peptide linkers

Info

Publication number
EP0941120A4
EP0941120A4 EP97946428A EP97946428A EP0941120A4 EP 0941120 A4 EP0941120 A4 EP 0941120A4 EP 97946428 A EP97946428 A EP 97946428A EP 97946428 A EP97946428 A EP 97946428A EP 0941120 A4 EP0941120 A4 EP 0941120A4
Authority
EP
European Patent Office
Prior art keywords
peptide linkers
branched peptide
branched
linkers
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97946428A
Other languages
German (de)
French (fr)
Other versions
EP0941120A1 (en
Inventor
Dalton King
Raymond A Firestone
Gene M Dubowchik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP0941120A1 publication Critical patent/EP0941120A1/en
Publication of EP0941120A4 publication Critical patent/EP0941120A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP97946428A 1996-11-05 1997-10-31 Branched peptide linkers Withdrawn EP0941120A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3036796P 1996-11-05 1996-11-05
US30367P 1996-11-05
PCT/US1997/019851 WO1998019705A1 (en) 1996-11-05 1997-10-31 Branched peptide linkers

Publications (2)

Publication Number Publication Date
EP0941120A1 EP0941120A1 (en) 1999-09-15
EP0941120A4 true EP0941120A4 (en) 2004-08-18

Family

ID=21853889

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97946428A Withdrawn EP0941120A4 (en) 1996-11-05 1997-10-31 Branched peptide linkers

Country Status (5)

Country Link
EP (1) EP0941120A4 (en)
JP (1) JP2001505194A (en)
AU (1) AU5159798A (en)
CA (1) CA2264610A1 (en)
WO (1) WO1998019705A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0961619A4 (en) * 1996-09-27 2001-09-26 Bristol Myers Squibb Co Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
ATE318618T1 (en) 1996-10-28 2006-03-15 Amersham Health As IMPROVEMENTS IN OR RELATED TO DIAGNOSTIC/THERAPEUTIC COMPOUNDS
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6545125B1 (en) * 1997-11-18 2003-04-08 Chugai Seiyaku Kabushiki Kaisha Compounds with antitumor activity
US6835807B1 (en) * 1998-05-22 2004-12-28 Daiichi Pharmaceuticals Co., Ltd. Drug complex and drug delivery system
CA2348931A1 (en) 1998-10-30 2000-05-11 Daiichi Pharmaceutical Co., Ltd. Dds compound and method for measurement thereof
EP1154782A4 (en) * 1999-02-24 2002-09-25 Uab Research Foundation Taxane derivatives for targeted therapy of cancer
JP2002542304A (en) * 1999-04-28 2002-12-10 ベクトレイムド インコーポレイテッド Enzymatically activated polymerized drug conjugate
DE60032633T2 (en) 1999-11-24 2007-10-04 Immunogen Inc., Cambridge CYTOTOXIC AGENTS CONTAINING TAXANE AND ITS THERAPEUTIC APPLICATION
DE10048417A1 (en) * 2000-09-29 2002-04-11 Roche Diagnostics Gmbh Branched linker connections
US6825166B2 (en) 2001-03-23 2004-11-30 Tapestry Pharmaceuticals, Inc. Molecular conjugates for use in treatment of cancer
US20060246066A1 (en) * 2001-12-17 2006-11-02 Morgan Bryan P Cleavable reagents for specific delivery to disease sites
KR20050032110A (en) 2002-08-02 2005-04-06 이뮤노젠 아이엔씨 Cytotoxic agents containing novel potent taxanes and their therapeutic use
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
AU2003256038A1 (en) * 2002-08-30 2004-03-19 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
EP1560599A1 (en) 2002-11-14 2005-08-10 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
US6906158B2 (en) 2003-03-13 2005-06-14 Irm, Llc Compositions and methods of vinyl oxazolone polymerization
US20040228831A1 (en) * 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
WO2005014823A2 (en) * 2003-08-05 2005-02-17 Wisconsin Alumni Research Foundation Targeted carrier fusions for delivery of chemotherapeutic agents
EP2311881A3 (en) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto binding molecules
CA2927045A1 (en) * 2006-10-03 2008-04-10 Muthiah Manoharan Lipid containing formulations
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
CA2860579A1 (en) 2012-01-10 2013-07-18 Biogen Idec Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
WO2014194030A2 (en) * 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
CN105873614B (en) * 2013-12-16 2020-10-30 基因泰克公司 Peptidomimetic compounds and antibody-drug conjugates thereof
ES2885686T3 (en) 2014-02-17 2021-12-15 Seagen Inc Hydrophilic Antibody-Drug Conjugates
EP3129065A4 (en) 2014-03-12 2018-01-24 Invictus Oncology Pvt. Ltd. Targeted drug delivery through affinity based linkers
KR101628872B1 (en) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 Compounds comprising self-immolative group
CN108064246A (en) 2015-06-15 2018-05-22 基因泰克公司 Antibody and immune conjugate
CN113599533A (en) * 2015-11-25 2021-11-05 乐高化学生物科学股份有限公司 Antibody-drug conjugates comprising branched linkers and methods related thereto
CA3006247A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Conjugates comprising peptide groups and methods related thereto
AU2016359230B2 (en) 2015-11-25 2020-04-23 Legochem Biosciences, Inc. Conjugates comprising self-immolative groups and methods related thereto
KR101938800B1 (en) 2017-03-29 2019-04-10 주식회사 레고켐 바이오사이언스 Pyrrolobenzodiazepine dimer prodrug and its ligand-linker conjugate compound
EP3755707A1 (en) 2018-02-20 2020-12-30 Seagen Inc. Hydrophobic auristatin f compounds and conjugates thereof
WO2019215510A2 (en) 2018-05-09 2019-11-14 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
KR20210028544A (en) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 Antibody-drug conjugate comprising antibody binding to antibody against human ROR1 and its use
JP2023536192A (en) 2020-08-03 2023-08-23 バイスクルテクス・リミテッド peptide-based linker
JP2023544990A (en) 2020-09-30 2023-10-26 エフ． ホフマン－ラ ロシュ アーゲー Bacterial pili protein complex FimGt-DsF stabilizing protein complex for producing filamentous phages
EP4349373A1 (en) * 2021-06-01 2024-04-10 Ajinomoto Co., Inc. Conjugate of antibody and functional substance or salt of said conjugate, and compound for use in production of said conjugate or salt of said compound

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084560A (en) * 1986-06-30 1992-01-28 Oncogen Immunoconjugates and methods for their use in tumor therapy
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5563250A (en) * 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US5017693A (en) * 1987-12-02 1991-05-21 Neorx Corporation Methods for introducing a sulfhydryl amino or hydroxyl groups to a compound
FI102355B1 (en) * 1988-02-11 1998-11-30 Bristol Myers Squibb Co A method for preparing anthracycline immunoconjugates having a linking spacer
US5252713A (en) * 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
IT1240643B (en) * 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa BIOLOGICALLY ACTIVE PEPTIDES CONTAINING IN 2-ALCHYL TRIPTOFANE CHAIN
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
ATE169031T1 (en) * 1991-04-05 1998-08-15 Univ Washington CELL RECEPTOR SPECIFIC MONOCLONAL ANTIBODIES AGAINST STEM CELL FACTOR RECEPTOR
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DUBOWCHIK GENE M ET AL: "Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 11, 3 June 2002 (2002-06-03), pages 1529 - 1532, XP002284221, ISSN: 0960-894X *
KING H D ET AL: "Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates.", BIOCONJUGATE CHEMISTRY. UNITED STATES 1999 MAR-APR, vol. 10, no. 2, March 1999 (1999-03-01), pages 279 - 288, XP002284220, ISSN: 1043-1802 *
See also references of WO9819705A1 *
SHIH L B ET AL: "ANTHRACYCLINE IMMUNOCONJUGATES PREPARED BY A SITE-SPECIFIC LINKAGE VIA AN AMINODEXTRAN INTERMEDIATE CARRIER", CANCER RESEARCH, vol. 51, no. 16, 1991, pages 4192 - 4198, XP001181850, ISSN: 0008-5472 *
WILLNER DAVID ET AL: "(6-Maleimidocaproyl)hydrazone of doxorubicin-A new derivative for the preparation of immunoconjugates of doxorubicin", BIOCONJUGATE CHEMISTRY, vol. 4, no. 6, 1993, pages 521 - 527, XP002284219, ISSN: 1043-1802 *

Also Published As

Publication number Publication date
CA2264610A1 (en) 1998-05-14
EP0941120A1 (en) 1999-09-15
JP2001505194A (en) 2001-04-17
WO1998019705A1 (en) 1998-05-14
AU5159798A (en) 1998-05-29

Similar Documents

Publication Publication Date Title
EP0941120A4 (en) Branched peptide linkers
HRP970308A2 (en) Peptide derivatives
GB9702377D0 (en) Peptide derivatives
PL318017A1 (en) Peptides
GB9718110D0 (en) Peptides
GB9624562D0 (en) Peptide derivatives
GB9700154D0 (en) Peptides
GB9425380D0 (en) Peptides
GB9627114D0 (en) Multiple branch peptide constructions
EP0996457A4 (en) Fsh-releasing peptides
EP0935608A4 (en) Cytotoxic peptides
GB9519511D0 (en) Peptides
GB9613705D0 (en) Novel peptides
AUPO324096A0 (en) Linker peptide
GB9425381D0 (en) Peptides
GB9625227D0 (en) Peptides
GB9612648D0 (en) Peptides
GB9606765D0 (en) Peptides
GB9608430D0 (en) Peptides
GB9626362D0 (en) Peptides
SG55039A1 (en) Peptides
GB9605904D0 (en) Peptides
GB9709607D0 (en) Peptide derivatives
GB9603855D0 (en) Peptide derivatives
GB9611881D0 (en) Peptide derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990607

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 5/08 B

Ipc: 7C 07K 5/10 B

Ipc: 7C 07K 5/06 B

Ipc: 7A 61K 47/48 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040701

17Q First examination report despatched

Effective date: 20050801

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090310